ImmunityBio prices $100M public offering at $3/sh and restructures $505M Nant Capital note

ImmunityBio, Inc.

Public offering of 33.3M shares at $3/sh for gross proceeds ~$100M; net to company ~$93.1M from firm shares.
Underwriters have 30-day option to purchase additional 5M shares at $3/sh; potential net proceeds $107.2M.
Concurrent debt restructuring: Nant Capital notes consolidated into $505M note due Dec 2027, interest SOFR+8%, convertible at $5.427/sh.
Limited consent from Oberland Capital (RIPA) obtained for the debt restructuring.
Net proceeds intended for ANKTIVA commercialization, BCG-naïve NMIBC and NSCLC trials, R&D, working capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.